CLAIMS

[Claim 1]

A benzazepine compound of Formula (1):



(1)

wherein R^1 is deuterium, OH, COOH, optionally substituted C_{1-6} alkyl, optionally substituted C_{1-6} alkyl-O-CO-, or optionally substituted C_{2-6} alkenyl;

L is a direct bond or -C(=O)-NH-;

Ring A^1 is a hydrocarbon ring or heterocycle;

Ring A^2 is a hydrocarbon ring or heterocycle; and

each of Rings A^1 and A^2 may have at least one substituent, or a salt thereof.

[Claim 2]

The compound according to claim 1, wherein Ring A^1 is a saturated or unsaturated 3- to 8-membered monocyclic hydrocarbon ring, or a saturated or unsaturated 3- to 15-membered monocyclic, bicyclic, or tricyclic heterocycle comprising as the ring member 1 to 5 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur,

Ring A^2 is a saturated or unsaturated 3- to 8-membered monocyclic hydrocarbon ring, or a saturated or unsaturated 3- to 15-membered monocyclic, bicyclic, or tricyclic heterocycle comprising as the ring member 1 to 5 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, and

each of Rings A^1 and A^2 may have at least one substituent, or a salt thereof.

[Claim 3]

The compound according to either claim 1 or 2, or a salt thereof, wherein Ring A^1 is a saturated or unsaturated 3- to 8-membered monocyclic hydrocarbon ring, a saturated or unsaturated 5- or 6-membered heteromonocycle comprising as the ring heteroatom 1 to 4 nitrogen atoms, a saturated or unsaturated 7- to 15-membered heterobicycle comprising as the ring heteroatom 1 to 5 nitrogen atoms, a saturated or unsaturated 5- or 6-membered heteromonocycle comprising as the ring heteroatom 1 or 2 oxygen atoms and at least one nitrogen atom, or a saturated or unsaturated 5- or 6-membered heteromonocycle comprising as the ring heteroatom 1 or 2 sulfur atoms and at least one nitrogen atom,

Ring A^2 is a saturated or unsaturated 3- to 8-membered monocyclic hydrocarbon

ring, a saturated or unsaturated 5- or 6-membered heteromonocycle comprising as the ring heteroatom 1 to 4 nitrogen atoms, a saturated or unsaturated 5- or 6-membered heteromonocycle comprising as the ring heteroatom 1 or 2 oxygen atoms, a saturated or unsaturated 7- to 12-membered heterobicycle comprising as the ring heteroatom 1 to 3 oxygen atoms, a saturated or unsaturated 5- or 6-membered heteromonocycle comprising as the ring heteroatom 1 or 2 sulfur atoms, a saturated or unsaturated 7- to 15-membered heterobicycle comprising as the ring heteroatom 1 to 5 nitrogen atoms, a saturated or unsaturated 5- or 6-membered heteromonocycle comprising as the ring heteroatom 1 or 2 oxygen atoms and at least one nitrogen atom, or a saturated or unsaturated 5- or 6-membered heteromonocycle comprising as the ring heteroatom 1 or 2 sulfur atoms and at least one nitrogen atom, and

each of Rings A^1 and A^2 may have at least one substituent.

[Claim 4]

The compound according to any one of claims 1 to 3, wherein Ring A^1 is benzene, pyridine, pyrazine, or tetrahydroisoquinoline and Ring A^1 may have 1 to 4 substituents independently selected from the group consisting of optionally substituted $C_{1\text{-}6}$ alkyl, optionally substituted $C_{1\text{-}6}$ alkyl-O-, halogen, and oxo;

Ring A^2 is benzene, pyridine, furan, thiophene, or tetrahydroisoquinoline and Ring A^2 may have 1 to 4 substituents independently selected from the group consisting of optionally substituted $C_{1\text{-}6}$ alkyl, optionally substituted $C_{1\text{-}6}$ alkyl-O-, optionally substituted $C_{3\text{-}6}$ cycloalkyl, halogen, oxo, optionally substituted phenyl, and optionally substituted pyridyl,

provided that when Ring A^2 has multiple substituents on its ring carbon atoms, then the substituents may combine together with the carbon atoms to form $C_{3\text{-}6}$ cycloalkyl; or a salt thereof.

[Claim 5]

The compound according to claim 4, wherein, in Ring A^1, a substituent of the optionally substituted $C_{1\text{-}6}$ alkyl or optionally substituted $C_{1\text{-}6}$ alkyl-O- is each independently the same or different 1 to 3 groups selected from the group consisting of halogen and $C_{1\text{-}6}$ alkyl-O-,

in Ring A^2, a substituent of the optionally substituted $C_{1\text{-}6}$ alkyl or optionally substituted $C_{1\text{-}6}$ alkyl-O- is each independently the same or different 1 to 3 halogen, a substituent of the optionally substituted $C_{3\text{-}6}$ cycloalkyl is the same or different 1 to 3 halogen, a substituent of the optionally substituted phenyl is 1 to 3 groups independently selected from the group consisting of halogen, $C_{1\text{-}6}$ alkyl, and $C_{1\text{-}6}$ alkyl-O-, and a substituent of the optionally substituted pyridyl is the same or different 1 to 3 halogen, or a salt thereof.

[Claim 6]

The compound according to any one of claims 1 to 5, wherein R^1 is deuterium; OH; COOH; $C_{1\text{-}6}$ alkyl optionally substituted with 1 to 3 groups independently selected from the group consisting of optionally substituted amino, optionally substituted $C_{1\text{-}6}$ alkyl-O-, optionally substituted $C_{1\text{-}6}$ alkyl-SO_2-O-, optionally substituted silyl-O-, OH, optionally substituted $C_{1\text{-}6}$ alkyl-COO-, tetrahydropyranyl-O-, thiazolyl, and pyridyl; optionally substituted $C_{1\text{-}6}$ alkyl-O-CO-; or optionally substituted $C_{2\text{-}6}$ alkenyl,

the optionally substituted amino is amino optionally substituted with 1 or 2 groups

independently selected from the group consisting of C_{1-6} alkyl optionally substituted with OH, optionally substituted C_{1-6} alkyl-SO_2-, optionally substituted C_{1-6} alkyl-O-CO-, and benzyl-O-CO-,

the optionally substituted C_{1-6} alkyl in the optionally substituted C_{1-6} alkyl-O-, optionally substituted C_{1-6} alkyl-SO_2-, optionally substituted C_{1-6} alkyl-SO_2-O-, optionally substituted C_{1-6} alkyl-COO-, and optionally substituted C_{1-6} alkyl-O-CO- is C_{1-6} alkyl optionally substituted with 1 to 3 groups independently selected from the group consisting of halogen, C_{1-6} alkyl-O-, optionally substituted phenyl, optionally substituted phenyl-SO_2-NH-, and naphthalenyl-SO_2-NH-, the optionally substituted phenyl being phenyl optionally substituted with 1 to 3 groups independently selected from the group consisting of halogen, C_{1-6} alkyl, and NO_2,

the optionally substituted silyl-O- is silyl-O- optionally substituted with the same or different 1 to 3 C_{1-6} alkyl, and

the optionally substituted C_{2-6} alkenyl is C_{2-6} alkenyl optionally substituted with the same or different 1 to 3 halogen, or a salt thereof.

[Claim 7]
The compound according to any one of claims 1 to 6, wherein R^1 is deuterium; OH; or C_{1-6} alkyl optionally substituted with optionally substituted amino, optionally substituted C_{1-6} alkyl-O-, or OH,

the optionally substituted amino is amino optionally substituted with C_{1-6} alkyl optionally substituted with OH, and

the optionally substituted C_{1-6} alkyl-O- is C_{1-6} alkyl-O- optionally substituted with the same or different 1 to 3 halogen, or a salt thereof.

[Claim 8]
The compound according to any one of claims 1 to 7, wherein R^1 is C_{1-6} alkyl substituted with OH, or a salt thereof.

[Claim 9]
The compound according to any one of claims 1 to 8, wherein Ring A^1 is benzene optionally substituted with halogen, C_{1-6} alkyl, halo-C_{1-6} alkyl, C_{1-6} alkyl-O-, halo-C_{1-6} alkyl-O-, C_{1-6} alkyl-O-C_{1-6} alkyl-O-, halo-C_{1-6} alkyl-O-C_{1-6} alkyl-O-, C_{1-6} alkyl-O-halo-C_{1-6} alkyl-O-, or halo-C_{1-6} alkyl-O-halo-C_{1-6} alkyl-O-; pyridine optionally substituted with halogen; pyrazine; or tetrahydroisoquinoline optionally substituted with oxo; and

Ring A^2 is benzene optionally substituted with 1 to 3 groups independently selected from the group consisting of halogen, C_{1-6} alkyl, halo-C_{1-6} alkyl, C_{1-6} alkyl-O-, halo-C_{1-6} alkyl-O-, C_{3-6} cycloalkyl, optionally substituted phenyl, and pyridyl, the optionally substituted phenyl being phenyl optionally substituted with halogen, C_{1-6} alkyl, halo-C_{1-6} alkyl, C_{1-6} alkyl-O-, or halo-C_{1-6} alkyl-O-; pyridine optionally substituted with C_{1-6} alkyl, halo-C_{1-6} alkyl, or phenyl; furan optionally substituted with C_{1-6} alkyl; thiophene optionally substituted with C_{1-6} alkyl; or tetrahydroisoquinoline optionally substituted with 1 to 3 groups independently selected from the group consisting of halogen, C_{1-6} alkyl, and oxo, provided that when tetrahydroisoquinoline has multiple C_{1-6} alkyl groups on its ring carbon atoms, then the C_{1-6} alkyl groups may combine together with the carbon atoms to form C_{3-6} cycloalkyl, or a salt thereof.

[Claim 10]

The compound according to any one of claims 1 to 9, wherein R^1 is C_{1-6} alkyl substituted with OH,

Ring A^1 is benzene optionally substituted with halogen, C_{1-6} alkyl, C_{1-6} alkyl-O-, or C_{1-6} alkyl-O-C_{1-6} alkyl-O-; or pyridine optionally substituted with halogen, and

Ring A^2 is benzene optionally substituted with 1 to 3 groups independently selected from the group consisting of halogen, C_{1-6} alkyl, halo-C_{1-6} alkyl, C_{1-6} alkyl-O-, halo-C_{1-6} alkyl-O-, C_{3-6} cycloalkyl, optionally substituted phenyl, and pyridyl, the optionally substituted phenyl being phenyl optionally substituted with halogen, C_{1-6} alkyl, halo-C_{1-6} alkyl, C_{1-6} alkyl-O-, or halo-C_{1-6} alkyl-O-, or a salt thereof.

[Claim 11]
The compound according to any one of claims 1 to 9, wherein R^1 is C_{1-6} alkyl substituted with OH,

Ring A^1 is benzene optionally substituted with halogen, C_{1-6} alkyl-O-, or halo-C_{1-6} alkyl-O-; or pyridine, and

Ring A^2 is benzene optionally substituted with 1 to 3 groups independently selected from the group consisting of halogen, C_{1-6} alkyl, halo-C_{1-6} alkyl, and phenyl optionally substituted with halogen; pyridine optionally substituted with phenyl or halo-C_{1-6} alkyl; or tetrahydroisoquinoline optionally substituted with 1 to 3 groups independently selected from the group consisting of halogen and oxo, or a salt thereof.

[Claim 12]
The compound according to any one of claims 1 to 11, wherein L is -C(=O)-NH-, or a salt thereof.

[Claim 13]
A compound, or a salt thereof, selected from the following compound group





5



[Claim 14]
A vasopressin receptor antagonist comprising a compound according to any one of claims 1 to 13 or a salt thereof.

[Claim 15]
A pharmaceutical composition, comprising a compound according to any one of claims 1 to 13 or a salt thereof, for treating, preventing, and/or diagnosing a disease selected from the group consisting of Meniere's disease, hypertension, edema, ascites, heart failure, renal dysfunction, renal failure, polycystic kidney disease, syndrome of inappropriate vasopressin secretion, hepatic cirrhosis, hyponatremia, hypokalemia, diabetes, circulation insufficiency, kinesia, water metabolism disorder, and ischemic disorder.

[Claim 16]
A pharmaceutical composition, comprising a compound according to any one of claims 1 to 13 or a salt thereof, for use in treating, preventing, and/or diagnosing a disease selected from the group consisting of Meniere's disease, hypertension, edema, ascites, heart failure, renal dysfunction, renal failure, polycystic kidney disease, syndrome of inappropriate vasopressin secretion, hepatic cirrhosis, hyponatremia, hypokalemia, diabetes, circulation insufficiency, kinesia, water metabolism disorder, and ischemic disorder.

[Claim 17]
Use of a compound according to any one of claims 1 to 13 or a salt thereof in the manufacture of a medicament for treating, preventing, and/or diagnosing a disease selected from the group consisting of Meniere's disease, hypertension, edema, ascites, heart failure, renal dysfunction, renal failure, polycystic kidney disease, syndrome of inappropriate vasopressin secretion, hepatic cirrhosis, hyponatremia, hypokalemia, diabetes, circulation insufficiency, kinesia, water metabolism disorder, and ischemic disorder.